AMNEAL PHARMACEUTICALS, INC. Proceeds from Contributed Capital
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Proceeds from Contributed Capital of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromContributedCapital · last filed 2021-03-01
- AMNEAL PHARMACEUTICALS, INC. proceeds from contributed capital for the quarter ending 2019-12-31 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. proceeds from contributed capital for the quarter ending 2019-09-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. proceeds from contributed capital for the quarter ending 2018-12-31 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. proceeds from contributed capital for the quarter ending 2018-09-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. proceeds from contributed capital for fiscal 2020 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. proceeds from contributed capital for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- AMNEAL PHARMACEUTICALS, INC. proceeds from contributed capital for fiscal 2018 was $27.74M, a 69255.00% increase from fiscal 2017.
- AMNEAL PHARMACEUTICALS, INC. proceeds from contributed capital for fiscal 2017 was $40.00K.
| Period end | Proceeds from Contributed Capital 3 month | Proceeds from Contributed Capital 6 month | Proceeds from Contributed Capital 9 month | Proceeds from Contributed Capital 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $27.74M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $27.74M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $27.74M 10-Q · filed 2019-08-05 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $40.00K 10-K · filed 2020-03-02 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $40.00K 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $40.00K 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |